Sexual-function peptides: the evidence

If you are weighing peptides for sexual function, the honest starting point is that the evidence is thin almost everywhere and solid in only one place. One molecule, bremelanotide (PT-141, sold as Vyleesi), has randomised controlled trial support, and it has that support for a single use: low sexual desire in premenopausal women^[1]. Everything else marketed for libido or erectile function rests on preclinical work, mechanism inference, or user reports.

The one peptide with real trial evidence

The trial base for bremelanotide is the RECONNECT phase 3 programme: two randomised, double-blind, placebo-controlled trials (BMT-301 and BMT-302) in premenopausal women with acquired, generalised hypoactive sexual desire disorder, the diagnosis of persistently low desire that causes marked distress. Women self-administered the 1.75 mg subcutaneous dose or placebo as needed over a 24-week core period. Across roughly 1,247 women, bremelanotide beat placebo on both co-primary endpoints, desire and distress, at P below .001. The gains were statistically significant but modest: about 0.35 on the desire domain and a 0.33 reduction on the distress item, not a rebuilt sex life^[1].

A 52-week open-label extension of the same programme reported no new safety signals and sustained the improvement, which is the strongest durability evidence any sexual-function peptide has produced^[2]. On that basis the US Food and Drug Administration approved bremelanotide as Vyleesi in June 2019, dosed at 1.75 mg by subcutaneous injection at least 45 minutes before anticipated sexual activity, with no more than eight doses a month^[3].

Where the evidence thins out

The approved evidence stops at premenopausal women with HSDD. It does not extend to men, to postmenopausal women, or to on-demand use for erectile function. For men in particular there are no controlled trials. A 2026 paper in the Journal of Clinical Psychopharmacology makes the point in its own title, asking whether bremelanotide should even be considered for arousal and desire disorders in men^[4]. That is a question the field is still posing, not one the data has settled.

The original 1990s work did test an intranasal form for male erectile dysfunction, but the FDA halted it in 2007 over blood-pressure increases, and the subcutaneous product that followed was confined to women. Grey-market use of PT-141 by men, on dosing schedules no trial has studied, sits outside both the approved label and the controlled evidence. We report that reality because readers meet it. We do not endorse it.

How to weight what you read

A simple rule helps when you sort claims about these peptides. Weight regulator-reviewed trial data highest: the FDA label, the RECONNECT trials, and independent synthesis of them. A 2026 systematic review and meta-analysis of female sexual dysfunction treatments, covering 26 randomised trials, placed bremelanotide among the options with measurable benefit and concluded that it improves both desire and arousal^[5]. Weight mechanism and animal studies below that, because a receptor rationale is not an outcome. Weight vendor marketing and forum anecdote lowest, because they carry no controlled data at all.

One framing is worth correcting directly. Bremelanotide is sometimes described as working on dopamine pathways. The label and the trial literature describe it instead as a melanocortin-receptor agonist acting in the brain, with any downstream dopamine effect inferred rather than measured. When a mechanism is stated more confidently than the evidence supports, treat it as shorthand, not fact. The same caution applies to any peptide sold with a confident story about how it works but no trial showing that it does.

The safety numbers, and what we still do not know

Even in the approved use, the tolerability cost is real. In the phase 3 trials about 40% of treated women had nausea, 13% needed an anti-emetic for it, and 8% stopped treatment because of it. Bremelanotide also raised blood pressure transiently, by roughly 6 mmHg systolic and 3 mmHg diastolic, which is why uncontrolled hypertension and known cardiovascular disease are contraindications on the label^[3]. Flushing affected about a fifth of women and headache roughly one in eight over 52 weeks of follow-up^[2]. Those figures come from the studied population. In off-label male or postmenopausal use, none of this has been characterised at all, so the real-world risk in the people most likely to buy PT-141 online is simply unknown.

So the evidence map is lopsided. One peptide, one indication, one population, backed by real trials. Everything else is unproven. Outside the United States the gap is wider still, because there is no European or UK marketing authorisation for bremelanotide, a point we track on the PT-141 regulation page. If you are considering any peptide for sexual function, the decision belongs with a clinician who knows your medical history, not with a vendor's product page.